Dupixent® (dupilumab) approved by european commission as the first and only targeted medicine indicated for eosinophilic esophagitis

A pproximately 60% of patients aged 12 years and older treated with dupixent 300 mg weekly in the pivotal trial experienced histological disease remission; patients also significantly improved their ability to swallow compared to placebo
REGN Ratings Summary
REGN Quant Ranking